ATIM-26. IMMUNOLOGIC TRENDS ASSOCIATED WITH PATIENT OUTCOMES IN A PHASE 1 CLINICAL TRIAL OF TOCA 511 AND TOCA FC IN RECURRENT HIGH GRADE GLIOMA

Toca 511 (vocimagene amiretrorepvec) is a cancer selective, retroviral replicating vector encoding a codon optimized, heat stabilized cytosine deaminase that converts Toca FC (extended-release 5- fluorocytosine, 5-FC) into the anticancer agent 5-fluorouracil. Preclinical evidence demonstrates that t...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Accomando, William, Cloughesy, Timothy, Kalkanis, Steven, Mikkelsen, Tom, Landolfi, Joseph, Carter, Bob, Chen, Clark, Vogelbaum, Michael, Elder, James, Piccioni, David, Walbert, Tobias, Hogan, Daniel, Diago, Oscar, Gammon, Dawn, Haghighi, Ali, Kheoh, Thian, Gruber, Harry, Jolly, Douglas, Ostertag, Derek
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2018
Soggetti:
Abstracts
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216133/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.021
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi